Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 0.87 |
| ▸ | TP53 | P04637 | 7/20 | 0.87 |
| ▸ | TLR4 | O00206 | 2/20 | 0.73 |
| ▸ | POLB | P06746 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16896094 | 1.00 | LMNA (0.87) | LMNATP53TLR4POLBMEN1 | |
| SCHEMBL16896209 | 1.00 | LMNA (0.87) | LMNATP53TLR4POLBMEN1 | |
| SCHEMBL16896049 | 0.99 | LMNA (0.85) | LMNATP53TLR4POLBMEN1 | |
| SCHEMBL16896219 | 0.97 | LMNA (0.82) | LMNATP53TLR4POLBMEN1 | |
| SCHEMBL16896232 | 0.92 | LMNA (0.75) | LMNATP53TLR4POLBMEN1 | |
| SCHEMBL19507992 | 0.91 | LMNA (0.73) | LMNATP53TLR4POLBMEN1 | |
| SCHEMBL16896106 | 0.91 | TP53 (0.81) | LMNATP53TLR4POLBMEN1 | |
| SCHEMBL16896225 | 0.88 | LMNA (0.74) | LMNATP53TLR4POLBMEN1 | |
| SCHEMBL16896047 | 0.88 | LMNA (0.74) | LMNATP53TLR4POLBMEN1 | |
| SCHEMBL16896199 | 0.85 | LMNA (0.68) | LMNATP53TLR4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210299286-A1 | TETRAZINES FOR HIGH CLICK CONJUGATION YIELD IN VIVO AND HIGH CLICK RELEASE YIELD | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-09-30 | — | — | US | disclosed |
| US-20210299286-A1 | TETRAZINES FOR HIGH CLICK CONJUGATION YIELD IN VIVO AND HIGH CLICK RELEASE YIELD | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-09-30 | — | — | US | disclosed |
| EP-3787691-A1 | TETRAZINES FOR HIGH CLICK CONJUGATION YIELD IN VIVO AND HIGH CLICK RELEASE YIELD | Tagworks Pharmaceuticals B.V. (NL) | 2021-03-10 | — | — | EP | disclosed |
| US-20180110784-A1 | SYNTHETIC TLR4 AND TLR7 LIGANDS TO PREVENT, INHIBIT OR TREAT LIVER DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-04-26 | — | — | US | disclosed |
| US-20180110784-A1 | SYNTHETIC TLR4 AND TLR7 LIGANDS TO PREVENT, INHIBIT OR TREAT LIVER DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-04-26 | — | — | US | disclosed |
| US-9505768-B2 | Compositions and methods for modulating TLR4 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505768-B2 | Compositions and methods for modulating TLR4 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505768-B2 | Compositions and methods for modulating TLR4 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150197527-A1 | COMPOSITIONS AND METHODS FOR MODULATING TLR4 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-07-16 | — | — | US | disclosed |
| US-20150197527-A1 | COMPOSITIONS AND METHODS FOR MODULATING TLR4 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-07-16 | — | — | US | disclosed |
| US-20150197527-A1 | COMPOSITIONS AND METHODS FOR MODULATING TLR4 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180110784-A1 | SYNTHETIC TLR4 AND TLR7 LIGANDS TO PREVENT, INHIBIT OR TREAT LIVER DISEASE | TLR4, TLR9, TLR1 | LMNA 1948/4885TP53 2145/4885TLR4 1/4885 |
| US-20150197527-A1 | COMPOSITIONS AND METHODS FOR MODULATING TLR4 | TLR4, TLR3, TLR6 | LMNA 1484/4885TP53 1455/4885TLR4 1/4885 |
| US-20210299286-A1 | TETRAZINES FOR HIGH CLICK CONJUGATION YIELD IN VIVO AND HIGH CLICK RELEASE YIELD | FCER2, SQLE, TTL | LMNA 4762/4885TP53 4730/4885TLR4 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.